Fusen Pharmaceutical Company Limited (HKG:1652)
Hong Kong
· Delayed Price · Currency is HKD 1.130
-0.030 (-2.59%)
Apr 29, 2026, 3:57 PM HKT
HKG:1652 Revenue
In the year 2025, Fusen Pharmaceutical Company had annual revenue of 273.37M CNY, down -16.15%. Fusen Pharmaceutical Company had revenue of 162.08M in the half year ending December 31, 2025, a decrease of -29.28%.
Revenue
273.37M CNY
Revenue Growth
-16.15%
P/S Ratio
2.75
Revenue / Employee
272.00K CNY
Employees
1,005
Market Cap
835.41M HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 273.37M | -52.66M | -16.15% |
| Dec 31, 2024 | 326.03M | -239.58M | -42.36% |
| Dec 31, 2023 | 565.61M | 73.85M | 15.02% |
| Dec 31, 2022 | 491.76M | 106.09M | 27.51% |
| Dec 31, 2021 | 385.66M | -101.19M | -20.78% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pak Fah Yeow International | 214.28M |
| Zhongzhi Pharmaceutical Holdings | 1.93B |
| Lee's Pharmaceutical Holdings | 1.44B |
| China NT Pharma Group Company | 26.88M |
| Jilin Province Huinan Changlong Bio-pharmacy Company | 1.00B |
| Dawnrays Pharmaceutical (Holdings) | 1.37B |
| Chia Tai Enterprises International | 4.17B |
| Essex Bio-Technology | 1.81B |